Literature DB >> 23996864

c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.

A A Abou-Bakr1, A Elbasmi.   

Abstract

BACKGROUND: There is a need for informative molecular markers that provide prognostic information over and above that given by conventional pathologic parameters. This study examined the expression and potential prognostic value of c-MET in colorectal adenocarcinoma.
MATERIAL AND METHODS: Two-hundred and thirty cases were evaluable after tissue microarray construction and evaluated for c-MET expression by immunohistochemistry. The results were correlated with standard clinicopathologic prognostic factors. Cases were followed up for 5 years.
RESULTS: c-MET was highly expressed in 138 of 230 cases (60%). In normal tissues a negative or weak reaction was observed. Significantly higher c-MET expression was found in the metastatic group (p=0.04). No significant association was found in relation to age, sex, tumor site, tumor size, histological type, or tumor grade (p > 0.05). The 5-year disease free survival for patients with low levels of expression was significantly higher than that for patients with high levels (64% versus 45%, p=0.04).
CONCLUSION: c-MET seems to be a valuable biomarker in colorectal adenocarcinoma; overexpression is a useful prognostic indicator for metastasis and patient outcome. KEYWORDS: c-MET, prognosis, colorectal adenocarcinoma, tissue microarray.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996864

Source DB:  PubMed          Journal:  Gulf J Oncolog        ISSN: 2078-2101


  11 in total

1.  CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer.

Authors:  Ying Gao; Chunyu Li; Min Nie; Yao Lu; Shunsen Lin; Peng Yuan; Xun Sun
Journal:  Tumour Biol       Date:  2014-01-07

Review 2.  High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.

Authors:  HeLi Gao; Mei Guan; Zhao Sun; ChunMei Bai
Journal:  Tumour Biol       Date:  2015-01-31

3.  Thermoresponsive Collagen/Cell Penetrating Hybrid Peptide as Nanocarrier in Targeting-Free Cell Selection and Uptake.

Authors:  Myungeun Oh; Chloe Hu; Selina F Urfano; Merlyn Arostegui; Katarzyna Slowinska
Journal:  Anal Chem       Date:  2016-09-22       Impact factor: 6.986

4.  c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.

Authors:  Mariana Fathy Gayyed; Nehad M R Abd El-Maqsoud; Amr Abd El-Hameed El-Heeny; Mostafa Fuad Mohammed
Journal:  J Gastrointest Oncol       Date:  2015-12

Review 5.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

6.  Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients.

Authors:  An Na Seo; Kyoung Un Park; Gheeyoung Choe; Woo Ho Kim; Duck-Woo Kim; Sung-Bum Kang; Hye Seung Lee
Journal:  Tumour Biol       Date:  2015-07-10

7.  YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.

Authors:  Rebecca Senetta; Eleonora Duregon; Cristina Sonetto; Rossella Spadi; Massimiliano Mistrangelo; Patrizia Racca; Luigi Chiusa; Fernando H Munoz; Umberto Ricardi; Alberto Arezzo; Adele Cassenti; Isabella Castellano; Mauro Papotti; Mario Morino; Mauro Risio; Paola Cassoni
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

8.  A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

Authors:  Cathy Eng; Alberto Bessudo; Lowell L Hart; Aleksey Severtsev; Oleg Gladkov; Lothar Müller; Mikhail V Kopp; Vladimir Vladimirov; Robert Langdon; Bogdan Kotiv; Sandro Barni; Ching Hsu; Ellen Bolotin; Reinhard von Roemeling; Brian Schwartz; Johanna C Bendell
Journal:  Int J Cancer       Date:  2016-03-22       Impact factor: 7.396

9.  Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.

Authors:  He Li; Yi-Xin Chen; Jia-Gen Wen; Hong-Hao Zhou
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

10.  Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met.

Authors:  Keisuke Satoh; Satoshi Nimura; Mikiko Aoki; Makoto Hamasaki; Kaori Koga; Hiroshi Iwasaki; Yuichi Yamashita; Hiroaki Kataoka; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.